These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 7394464)

  • 1. [The bioavailability of orally administered drugs with special regard to the liver as a filter for foreign matter].
    Raaflaub J
    Schweiz Med Wochenschr; 1980 Mar; 110(10):354-62. PubMed ID: 7394464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biologic availability and "1st pass" effect of drugs].
    Rietbrock N; Keller F
    Fortschr Med; 1977 Jul; 95(28):1765-6, 1774-80. PubMed ID: 914146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique.
    von Richter O; Greiner B; Fromm MF; Fraser R; Omari T; Barclay ML; Dent J; Somogyi AA; Eichelbaum M
    Clin Pharmacol Ther; 2001 Sep; 70(3):217-27. PubMed ID: 11557909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating drug solubility in the gastrointestinal tract.
    Dressman JB; Vertzoni M; Goumas K; Reppas C
    Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bioavailability and its significance in pharmacotherapy].
    Wiela-Hojeńska A; Orzechowska-Juzwenko K
    Pol Merkur Lekarski; 2003 Jan; 14(79):89-93. PubMed ID: 12712840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450-mediated metabolism in the human gut wall.
    Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 May; 61(5):541-58. PubMed ID: 19405992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gastrointestinal microbiota as a site for the biotransformation of drugs.
    Sousa T; Paterson R; Moore V; Carlsson A; Abrahamsson B; Basit AW
    Int J Pharm; 2008 Nov; 363(1-2):1-25. PubMed ID: 18682282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the analysis and interpretation of bioavailability studies in man.
    Wagner JG
    Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.
    Cho HJ; Kim JE; Kim DD; Yoon IS
    Drug Dev Ind Pharm; 2014 Aug; 40(8):989-98. PubMed ID: 23981203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Varma MV; Obach RS; Rotter C; Miller HR; Chang G; Steyn SJ; El-Kattan A; Troutman MD
    J Med Chem; 2010 Feb; 53(3):1098-108. PubMed ID: 20070106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bioavailability and first-pass effects.
    Kwan KC
    Drug Metab Dispos; 1997 Dec; 25(12):1329-36. PubMed ID: 9394021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model.
    Paixão P; Gouveia LF; Morais JA
    Int J Pharm; 2012 Jun; 429(1-2):84-98. PubMed ID: 22449410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic model of presystemic metabolism.
    Colburn WA; Gibaldi M
    Drug Metab Dispos; 1978; 6(2):193-6. PubMed ID: 26536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of cyclodextrins for enhancing oral bioavailability.
    Carrier RL; Miller LA; Ahmed I
    J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral bioavailability and drug/carrier particulate systems].
    Wawrezinieck A; Péan JM; Wüthrich P; Benoit JP
    Med Sci (Paris); 2008; 24(6-7):659-64. PubMed ID: 18601886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the prediction and modeling of oral absorption and bioavailability.
    Metcalfe PD; Thomas S
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):104-10. PubMed ID: 20047151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS; Breen PJ
    Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A timely reassessment of early prediction in the bioavailability of orally administered drugs.
    Larsen T; Link A
    Angew Chem Int Ed Engl; 2005 Jul; 44(29):4432-4. PubMed ID: 15984039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.